ZDHHC16 expression was significantly positive associated with clinicopathological stage, tumor grade and ICB immunotherapy key genes (i.e., CD274, CTLA4, HAVCR2 and PDCD1, etc.). This evidence concerns the gene CTLA4 and neoplasm.